Mechanisms of transcoelomic metastasis in ovarian cancer
- PMID: 17081918
- DOI: 10.1016/S1470-2045(06)70939-1
Mechanisms of transcoelomic metastasis in ovarian cancer
Abstract
Metastasis from epithelial ovarian cancer can occur via the transcoelomic, haematogeneous, or lymphatic route. Of these, transcoelomic metastasis is the most common, and is responsible for the greatest morbidity and mortality in women with this disease. Unfortunately, very little is known about the mechanisms behind this process. This review assesses the current evidence and ideas about the biology of transcoelomic dissemination. The mechanisms of cell detachment, migration, and implantation in transcoelomic metastasis are placed within the context of clinical observations of ovarian cancer to derive a stepwise hypothesis of this process. Evidence for transcoelomic dissemination versus transcoelomic metaplasia in ovarian cancer is presented. Future high throughput microarray studies that compare changes at a genomic and gene expression level between primary ovarian tumours and their peritoneal metastases are hoped to lead to a more conclusive picture of transcoelomic metastasis, and to delineate the key molecular players in this process. These studies might also result in the identification of potential new therapeutic targets in ovarian cancer.
Similar articles
-
Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.Cancer Genomics Proteomics. 2016 11-12;13(6):407-423. doi: 10.21873/cgp.20004. Cancer Genomics Proteomics. 2016. PMID: 27807064 Free PMC article. Review.
-
The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.Front Endocrinol (Lausanne). 2022 Apr 28;13:886533. doi: 10.3389/fendo.2022.886533. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35574025 Free PMC article. Review.
-
Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer.J Clin Invest. 2016 Nov 1;126(11):4157-4173. doi: 10.1172/JCI87252. Epub 2016 Oct 10. J Clin Invest. 2016. PMID: 27721235 Free PMC article.
-
Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition.Mol Cancer Ther. 2008 Oct;7(10):3441-51. doi: 10.1158/1535-7163.MCT-08-0417. Mol Cancer Ther. 2008. PMID: 18852147
-
Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles.Cell Oncol (Dordr). 2020 Aug;43(4):515-538. doi: 10.1007/s13402-020-00513-9. Epub 2020 May 16. Cell Oncol (Dordr). 2020. PMID: 32418122 Review.
Cited by
-
Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.Mol Cancer Ther. 2015 Apr;14(4):1035-47. doi: 10.1158/1535-7163.MCT-14-0800. Epub 2015 Feb 2. Mol Cancer Ther. 2015. PMID: 25646015 Free PMC article.
-
Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer.Oncotarget. 2015 Aug 7;6(22):18966-79. doi: 10.18632/oncotarget.3943. Oncotarget. 2015. PMID: 26136338 Free PMC article.
-
Exosomes: Key Factors in Ovarian Cancer Peritoneal Metastasis and Drug Resistance.Biomolecules. 2024 Sep 2;14(9):1099. doi: 10.3390/biom14091099. Biomolecules. 2024. PMID: 39334866 Free PMC article. Review.
-
Sentinel or Selective Omentectomy in Epithelial Ovarian Cancer: New Perspective.Indian J Surg Oncol. 2021 Mar;12(1):177-179. doi: 10.1007/s13193-020-01264-7. Epub 2021 Jan 3. Indian J Surg Oncol. 2021. PMID: 33814850 Free PMC article. No abstract available.
-
Development of adaptive anoikis resistance promotes metastasis that can be overcome by CDK8/19 Mediator kinase inhibition.bioRxiv [Preprint]. 2023 Dec 6:2023.12.04.569970. doi: 10.1101/2023.12.04.569970. bioRxiv. 2023. PMID: 38106208 Free PMC article. Preprint.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical